A NONIMMUNOSUPPRESSANT APPROACH TO PSORIASIS SUBJECTS: FOLLOWUPAND DATAANALYSIS

Mono- or combine immunosuppressants are commonly used for psoriasis; however the side effect caused by potent systemic immunosuppressants frequently incurred; moreover the inammation ares up shortly after immunosuppressants are discon- tinued. An alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. Aretrospective observational study consisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440 mg three times daily Psoriasis lesion evolution was photographed at monthly visit, and efcacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver function testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews. The effectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure , signicant improvements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of 16); the wave like evolution of psoriatic lesion appeared in prior immunosuppressants subjects.